Profusa Builds NVIDIA-Powered AI Portal for Continuous Biomarker Monitoring

ByRicardo
™

Company expects early 2026 rollout in EEA; doctor portal combines Lumee™ oxygen monitoring with NVIDIA NeMo to ship AI-driven medical workflows

Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a industrial stage digital well being firm pioneering a next-generation expertise platform enabling the continual monitoring of a person’s biochemistry, publicizes the adoption of NVIDIA expertise to energy an AI-driven perception portal for steady biochemistry monitoring. 

“We consider that real-time biochemistry information throughout a big inhabitants is a data-set that’s at the moment lacking to allow the success of the promise of AI-enabled enchancment in healthcare.  Profusa is uniquely positioned to offer this proprietary information set, linking therapeutic choices with real-time biochemistry adjustments, to generate useful insights which are missing at present.” Ben Hwang, Ph.D., Profusa’s Chairman and CEO commented, “By combining our Lumee platform with the trade main NVIDIA NeMo {hardware} and software program stack, we plan to construct an AI-fueled, scalable expertise spine for higher personalised sensor information accuracy and real-time sensor information connections with digital medical data (EMR), facilitating therapy and final result predictions, along with establishing a sturdy information base for medical literature for illness administration.”

Expected capabilities and have units from the doctor portal embrace:

  • Agentic medical workflows: A big language mannequin (LLM) powered assistant for clinicians that integrates with EMRs, wearables, and residential gadgets to help with notes, orders, care plans, distant physiologic monitoring (RPM)/distant therapeutic monitoring (RTM), triage, and escalations  
  • Evaluation and monitoring: Built-in experimentation and metrics to evaluate assistant high quality, drift, and security over time
  • Guardrails by design: Policy-aware orchestration to implement medical scope, information privateness, and protected responses throughout affected person and supplier experiences
  • Model coaching choices: From parameter-efficient tuning to post-training refinement of Profusa’s AI sign processing and medical reasoning elements
  • Time-aligned well being information graph: A longitudinal view that fuses Profusa biomarkers with EMR information (issues, meds, labs, vitals, imaging, notes), claims/pharmacy, wearables/IoT, genomics, and social determinants to energy predictions and training

“We consider physicians want reliable, always-on insights, no more dashboards.  Our intention is for this cutting-edge portal expertise to reply this want by translating uncooked optical indicators into dependable biometrics, offering actionable medical context.” concluded Dr. Hwang.

The portal might be utilized in mixture with Profusa’s Lumee oxygen optical hydrogel sensors and reader system, extending Profusa’s AI-enabled sign processing and care group instruments from clinician workplaces to distant affected person monitoring settings. Profusa expects an early 2026 rollout of the portal within the European Economic Area (EEA) —consisting of the EU, Lichtenstein, Norway, and Iceland — which accepts the CE Mark.

The publish Profusa Builds NVIDIA-Powered AI Portal for Continuous Biomarker Monitoring first appeared on AI-Tech Park.

Similar Posts